Akari Therapeutics PLCNASDAQ:AKTXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.2500
- TODAY'S CHANGE (%)0.2567 (6.4283%)
- Bid / Lots4.0100/ 1
- Ask / Lots4.4000/ 2
- Open / Previous Close4.0000 / 3.9933
- Day Range
- 52 Week Range
- Volume24,610
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AKTX |
|---|---|---|
| 09:32 ET | 566 | 4 |
| 09:41 ET | 1000 | 3.9999 |
| 10:10 ET | 1126 | 3.86 |
| 11:26 ET | 100 | 3.88 |
| 11:29 ET | 200 | 3.8986 |
| 11:54 ET | 7038 | 4 |
| 12:34 ET | 100 | 4.16 |
| 01:01 ET | 9098 | 4.25 |
| 01:08 ET | 100 | 4.26 |
| 01:15 ET | 142 | 4.4 |
| 01:33 ET | 528 | 4.13 |
| 01:37 ET | 2000 | 4.255 |
| 01:42 ET | 400 | 4.26 |
| 01:44 ET | 200 | 4.25 |
| 02:15 ET | 200 | 4.2599 |
| 02:54 ET | 250 | 4.12 |
| 03:34 ET | 196 | 4.2 |
| 03:59 ET | 502 | 4.25 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Akari Therapeutics PLC | 47.7M | 0.0x | --- |
Protara Therapeutics Inc | 47.2M | -0.6x | --- |
Vicapsys Life Sciences Inc | 48.4M | -46.1x | --- |
Lantern Pharma Inc | 48.8M | -2.8x | --- |
Reneo Pharmaceuticals Inc | 49.8M | -0.7x | --- |
Mira Pharmaceuticals Inc | 44.9M | -3.3x | --- |
Company Information
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
Contact Information
- Headquarters
- 22 BOSTON WHARF ROAD, FL 7BOSTON, MA, United States 02210
- Phone
- 646-350-0702
- Fax
- 646-843-9352
Executives
- Independent Chairman of the Board
- Raymond Prudo-chlebosz
- Interim President, Interim Chief Executive Officer, Director
- Samir Patel
- Interim Chief Financial Officer
- Wendy Dicicco
- Independent Director
- Michael Grissinger
- Independent Director
- Wa'el Hashad
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.7M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 597.7K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.86 |
EPS | --- |
Book Value | $-0.03 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
